Dundee University spin-out company Exscientia is a world leader at using artificial intelligence (AI) to automate drug design, which speeds up the development of drug candidates.
A new report by equity analyst Ian Jermin of Allenby Capital noted that a “similarly-sized” rival was recently valued at $2.1bn.
Exscientia was valued at £100 million in a funding round last year but several major deals with global pharmaceutical firms have propelled the firm’s value.
Exscientia is at the forefront of artificial intelligence (AI)-driven drug discovery and design. Frontier IP Group plc (LON:FIPP) as a 5% holding in Exscientia as of 30th June 2016.